8th Nov 2016- One NC small business program: Award of matching grant

Collaborations Pharmaceuticals, Inc. has been selected for a Stage 1 Grant Award of $32,346.50 under the One North Carolina SBIR/STTR Matching Funds Program Solicitation, Funding Opportunity Number NCBST-FY16-17M, closing on June 30, 2017 (the “Solicitation”). The Phase I Matching Funds Program is designed to award matching funds to North Carolina businesses who have been awarded a SBIR or STTR Phase I award.

 

This funding will be important as the company grows, hires staff and supports local businesses. We are very grateful for the support of the North Carolina Office of Science, Technology & Innovation.

16 -Aug 2016 - Collaborations Pharmaceuticals, Inc. and Rutgers announce NIH Award to develop treatments for tuberculosis

Fuquay-Varina, North Carolina – The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded $149,388 to Collaborations Pharma, Inc. (CPI) to initiate a partnership with Rutgers aimed at developing a series of compounds for treating tuberculosis (TB), an infectious disease generally affecting the lungs in humans and caused by the bacterium Mycobacterium tuberculosis (Mtb).

One-third of the global population is understood to be infected with TB and the disease continues to kill 1.5 million people every year and to infect approximately 9 million. Despite the availability of effective treatments for the disease, the combined impacts of drug resistance and morbidity of patients co-infected with HIV/AIDS have stimulated research on new quicker acting (less than the current six-month minimum) treatments efficacious against drug-resistant infections that are less toxic when used with anti-retroviral regimens for HIV/AIDS.

“We initially used Bayesian machine learning models to rediscover a class of compounds which seems to have been neglected for over 40 years ago. The compound we found has activity against drug-sensitive TB as well drug-resistant forms” said Sean Ekins, CEO CPI.

“To date my lab has made many analogs of the initial active compound we co-discovered with Dr. Ekins. Our plan is to focus on addressing limitations using computational models developed by CPI to see if we can arrive at a compound with good activity in an acute mouse model of the disease” said Dr. Joel S. Freundlich, Associate Professor of Pharmacology, Physiology & Neuroscience and Medicine at Rutgers University–New Jersey Medical School.

Dr. Freundlich has a chemical biology lab of eleven scientists that utilizes a multi-disciplinary approach to study infectious diseases, with a specific focus on tuberculosis. His lab will aim to identify potential drug candidates as well as the mechanism of action of this antitubercular class. Ultimately their goal is to optimize this compound class to develop a commercially viable new series of antibacterials.

“This work is a wonderful example of our efforts to involve outside companies in our search for novel antibacterials” said Dr. David Perlin, Executive Director, Professor at the Public Health Research Institute Center at Rutgers and Principal Investigator, NIH/NIAID Center of Excellence in Translational Research.

“We are very grateful to NIAID for funding this project as CPI is focused on collaborations with academia so that we can apply our computational approaches to real world applications that can impact research on neglected diseases” said Dr. Ekins.

About Rutgers New Jersey Medical School
Founded in 1954, Rutgers New Jersey Medical School is the oldest school of medicine in the state. Today it is part of Rutgers, The State University of New Jersey, and graduates approximately 170 physicians a year. Dedicated to excellence in education, research, clinical care and community outreach, the medical school comprises 22 academic departments and works with several healthcare partners, including its principal teaching hospital, Newark University Hospital. Its faculty consists of numerous world-renowned scientists and many of the region’s “top doctors.” New Jersey Medical School hosts more than 50 centers and institutes, including the Public Health Research Institute Center, the Global Tuberculosis Institute and the Neurological Institute of New Jersey. For more information please visit: njms.rutgers.edu

About Collaborations Pharmaceuticals, Inc.
Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and infectious diseases. We partner with academics or companies to identify and translate early preclinical to clinical stage assets. We have considerable experience of preclinical and computational approaches to drug discovery and toxicity prediction. For more information, please visit http://www.collaborationspharma.com/

For further information, please contact
Sean Ekins, Ph.D., D.Sc.
CEO and Founder
Collaborations Pharmaceuticals, Inc.
5616 Hilltop Needmore Road,
Fuquay Varina, NC 27526
collaborationspharma@gmail.com

Collaborations Pharmaceuticals participates in OpenZika launch

Zika Treatment Search Launched, Fueled By IBM’s World Community Grid Crowdsourced research project aimed at helping scientists cure debilitating disease
ARMONK, NY – 19 May 2016: IBM’s (NYSE: IBMWorld Community Grid and scientists are launching an international study to identify drug candidates to cure Zika, a fast spreading virus that the World Health Organization has declared a global public health emergency.

IBM and a global team of scientists are inviting anyone with a computer or Android device to join the #OpenZika project. Volunteers don’t need to provide time, expertise or money to help; they simply run an app on their Windows, Mac, Linux or Android devices that automatically performs virtual experiments for scientists whenever the machines are otherwise idle.

Through the OpenZika project, World Community Grid will power virtual experiments on compounds that could form the basis of antiviral drugs to cure the Zika virus, which has been linked to serious neurological disorders. With dramatically more speed than possible in a traditional lab, the project will screen compounds from existing molecule databases against models of Zika protein and crystal structures. Screening results will quickly be shared with the research community and general public. Promising compounds would then be tested in the collaborators’ laboratories.

For the OpenZika project, World Community Grid is working with an international team of researchers led in Brazil by the Federal University of Goias, and with support from Brazil’s Oswaldo Cruz Foundation (Fiocruz); Rutgers University’s New Jersey Medical SchoolCollaborations Pharmaceuticals, Inc.; and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego.

“Enlisting the help of World Community Grid volunteers will enable us to computationally evaluate over 20 million compounds in just the initial phase and potentially up to 90 million compounds in future phases,” said Carolina H. Andrade, Ph.D., professor at the Federal University of Goiás in Brazil and the lead researcher on the OpenZika project. “Running the OpenZika project on World Community Grid will allow us to greatly expand the scale of our project, and it will accelerate the rate at which we can obtain the results toward an antiviral drug for the Zika virus.”

The need for a treatment is acute as warmer weather approaches North America, creating an environment more conducive to Zika-carrying mosquitoes, and as international travelers contract and transmit the virus.

Other anti viral research efforts also hold promise. For example, IBM Research and Singapore’s Institute of Bioengineering and Nanotechnology announced that they have identified a macromolecule that could help prevent deadly viral infections such as Zika. IBM has provided its expertise and resources for other disease outbreaks, such as Ebola. For instance, IBM’s World Community Grid launched a project on Ebola research.

In addition, IBM has helped governments track diseases outbreaks.The company provided a citizen engagement and analytics system in Sierra Leone that enables communities affected by Ebola to communicate their issues and concerns directly to the government. For that pubic health emergency, IBM Research also created opinion-based heat-maps which correlated public sentiment to reported outbreak locations. IBM scientists have created a free, open source tool that helps scientists and public health officials create, use and study spatial and temporal models of emerging infectious diseases such as Zika.

As part of its citizenship program focused on innovative solutions to societal problems, IBM created World Community Grid in 2004 to address researchers’ critical need for supercomputing power. Partially hosted on IBM’s SoftLayer cloud technology, World Community Grid provides massive amounts of supercomputing power to scientists, free of charge. It does this by harnessing the unused computing power of volunteers’ computers and Android devices. More than three million computers and mobile devices used by nearly three quarters of one million people and 470 institutions across 80 countries have contributed virtual supercomputing power for more than two-dozen vitally important projects on World Community Grid over the last 11 years, at a value of more than $500 million.

World Community Grid has helped researchers identify new potential treatments for childhood cancer, identifying new materials for more efficient solar cells, and helping to identify how nanotechnology can filter water more efficiently. Many of these efforts might not have even been attempted without the free supercomputing power provided by IBM’s World Community Grid.

To perform such computational experiments, OpenZika researchers are using a widely used virtual screening tool called AutoDock VINA, developed by the Olson laboratory at The Scripps Research Institute. At its core, World Community Grid is enabled by Berkeley Open Infrastructure for Network Computing (BOINC), an open source platform developed at the University of California, Berkeley and with support from the National Science Foundation.

Volunteers can support the OpenZika search for a cure by joining World Community Grid. IBM also invites researchers to submit research project proposals to receive this free resource. For more information about IBM’s philanthropic efforts, please visit www.citizenIBM.com or follow @CitizenIBM on Twitter.

Contact(s) information

Ari Fishkind

IBM Media Relations

1 (914) 499-6420

fishkind@us.ibm.com

 

Angie Hu

IBM Media Relations

914-499-6532

ahu@us.ibm.com